Timothy R Angeli1, Peng Du1, David Midgley1, Niranchan Paskaranandavadivel1, Shameer Sathar1, Christopher Lahr2, Thomas L Abell3, Leo K Cheng1,4, Gregory O'Grady1,5. 1. Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand. 2. Department of Surgery, Mississippi Medical Center, Jackson, MS, USA. 3. Department of Gastroenterology, University of Louisville, Louisville, KY, USA. 4. Department of Surgery, Vanderbilt University, Nashville, TN, USA. 5. Department of Surgery, University of Auckland, Auckland, New Zealand.
Abstract
BACKGROUND AND AIMS: High-frequency gastric electrical stimulation (GES) has emerged as a therapy for gastroparesis, but the mechanism(s) of action remain unclear. There is a need to refine stimulation protocols for clinical benefit, but a lack of accurate techniques for assessing mechanisms in clinical trials, such as slow wave modulation, has hindered progress. We thereby aimed to assess acute slow wave responses to GES in gastroparesis patients using high-resolution (HR) (multi-electrode) mapping, across a range of stimulation doses achievable by the Enterra stimulation device (Medtronic Inc., MN, USA). MATERIALS AND METHODS: Patients with medically refractory gastroparesis (n = 8) undergoing device implantation underwent intraoperative HR mapping (256 electrodes). Baseline recordings were followed by four protocols of increasing stimulation intensity, with washout periods. Slow wave patterns, frequency, velocity, amplitude, and dysrhythmia rates were quantified by investigators blinded to stimulation settings. RESULTS: There was no difference in slow wave pattern, frequency, velocity, or amplitude between baseline, washout, and stimulation periods (all p > 0.5). Dysrhythmias included ectopic pacemakers, conduction blocks, retrograde propagation, and colliding wavefronts, and dysrhythmia rates were unchanged with stimulation off vs. on (31% vs. 36% duration dysrhythmic; p > 0.5). Symptom scores and gastric emptying were improved at 5.8 month follow-up (p < 0.05). CONCLUSIONS: High-frequency GES protocols achievable from a current commercial device did not acutely modulate slow wave activity or dysrhythmias. This study advances clinical methods for identifying and assessing therapeutic GES parameters, and can be applied in future studies on higher-energy protocols and devices.
BACKGROUND AND AIMS: High-frequency gastric electrical stimulation (GES) has emerged as a therapy for gastroparesis, but the mechanism(s) of action remain unclear. There is a need to refine stimulation protocols for clinical benefit, but a lack of accurate techniques for assessing mechanisms in clinical trials, such as slow wave modulation, has hindered progress. We thereby aimed to assess acute slow wave responses to GES in gastroparesis patients using high-resolution (HR) (multi-electrode) mapping, across a range of stimulation doses achievable by the Enterra stimulation device (Medtronic Inc., MN, USA). MATERIALS AND METHODS: Patients with medically refractory gastroparesis (n = 8) undergoing device implantation underwent intraoperative HR mapping (256 electrodes). Baseline recordings were followed by four protocols of increasing stimulation intensity, with washout periods. Slow wave patterns, frequency, velocity, amplitude, and dysrhythmia rates were quantified by investigators blinded to stimulation settings. RESULTS: There was no difference in slow wave pattern, frequency, velocity, or amplitude between baseline, washout, and stimulation periods (all p > 0.5). Dysrhythmias included ectopic pacemakers, conduction blocks, retrograde propagation, and colliding wavefronts, and dysrhythmia rates were unchanged with stimulation off vs. on (31% vs. 36% duration dysrhythmic; p > 0.5). Symptom scores and gastric emptying were improved at 5.8 month follow-up (p < 0.05). CONCLUSIONS: High-frequency GES protocols achievable from a current commercial device did not acutely modulate slow wave activity or dysrhythmias. This study advances clinical methods for identifying and assessing therapeutic GES parameters, and can be applied in future studies on higher-energy protocols and devices.
Authors: Timothy R Angeli; Peng Du; Niranchan Paskaranandavadivel; Patrick W M Janssen; Arthur Beyder; Roger G Lentle; Ian P Bissett; Leo K Cheng; Gregory O'Grady Journal: J Physiol Date: 2013-05-27 Impact factor: 5.182
Authors: G O'Grady; P Du; N Paskaranandavadivel; T R Angeli; W J E P Lammers; S J Asirvatham; J A Windsor; G Farrugia; A J Pullan; L K Cheng Journal: Neurogastroenterol Motil Date: 2012-07 Impact factor: 3.598
Authors: Timothy R Angeli; Leo K Cheng; Peng Du; Tim Hsu-Han Wang; Cheryl E Bernard; Maria-Giuliana Vannucchi; Maria Simonetta Faussone-Pellegrini; Christopher Lahr; Ryash Vather; John A Windsor; Gianrico Farrugia; Thomas L Abell; Gregory O'Grady Journal: Gastroenterology Date: 2015-04-08 Impact factor: 22.682
Authors: Madhusudan Grover; Gianrico Farrugia; Matthew S Lurken; Cheryl E Bernard; Maria Simonetta Faussone-Pellegrini; Thomas C Smyrk; Henry P Parkman; Thomas L Abell; William J Snape; William L Hasler; Aynur Ünalp-Arida; Linda Nguyen; Kenneth L Koch; Jorges Calles; Linda Lee; James Tonascia; Frank A Hamilton; Pankaj J Pasricha Journal: Gastroenterology Date: 2011-02-04 Impact factor: 22.682
Authors: Rachel Berry; Taimei Miyagawa; Niranchan Paskaranandavadivel; Peng Du; Timothy R Angeli; Mark L Trew; John A Windsor; Yohsuke Imai; Gregory O'Grady; Leo K Cheng Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-09-22 Impact factor: 4.052
Authors: Jonas F Schiemer; Karen Stumm; Karin H Somerlik-Fuchs; Klaus-Peter Hoffmann; Jan Baumgart; Werner Kneist Journal: Eur Surg Res Date: 2020-08-07 Impact factor: 1.745
Authors: T R Angeli; P Du; N Paskaranandavadivel; S Sathar; A Hall; S J Asirvatham; G Farrugia; J A Windsor; L K Cheng; G O'Grady Journal: Neurogastroenterol Motil Date: 2016-12-29 Impact factor: 3.598
Authors: Jonas F Schiemer; Axel Heimann; Karin H Somerlik-Fuchs; Roman Ruff; Klaus-Peter Hoffmann; Jan Baumgart; Manfred Berres; Hauke Lang; Werner Kneist Journal: J Neurogastroenterol Motil Date: 2019-07-01 Impact factor: 4.924
Authors: Leo K Cheng; Nipuni D Nagahawatte; Recep Avci; Peng Du; Zhongming Liu; Niranchan Paskaranandavadivel Journal: Front Neurosci Date: 2021-04-22 Impact factor: 5.152
Authors: Zahra Aghababaie; Niranchan Paskaranandavadivel; Satya Amirapu; Chih-Hsiang Alexander Chan; Peng Du; Samuel J Asirvatham; Gianrico Farrugia; Arthur Beyder; Gregory O'Grady; Leo K Cheng; Timothy R Angeli-Gordon Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-20 Impact factor: 4.052